ARGENT BIOPHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.415 AUD | +2.47% |
|
-3.49% | -12.63% |
| Sales 2022 | 4.73M 3.09M 247M | Sales 2023 | 3.39M 2.21M 177M | Capitalization | 16.75M 10.94M 876M |
|---|---|---|---|---|---|
| Net income 2022 | -20M -13.06M -1.05B | Net income 2023 | -20M -13.06M -1.05B | EV / Sales 2022 | 9.75 x |
| Net Debt 2022 | 2.47M 1.61M 129M | Net Debt 2023 | 9.51M 6.22M 498M | EV / Sales 2023 | 7.75 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 9.44% |
More Fundamentals
* Assessed data
| 1 week | -3.49% | ||
| Current month | +1.22% | ||
| 1 month | +5.06% | ||
| 3 months | +23.88% | ||
| 6 months | -79.25% | ||
| Current year | -12.63% |
1 week
0.41
0.44
1 month
0.400.45
3 years
0.3067.00
5 years
0.30130.00
10 years
0.30130.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.415 | +2.47% | 1,033 |
| 24/04/24 | 0.405 | -4.71% | 6,603 |
| 23/04/24 | 0.425 | -1.16% | 28,092 |
| 22/04/24 | 0.43 | 0.00% | 5,109 |
| 19/04/24 | 0.43 | +4.88% | 4,257 |
Delayed Quote Australian S.E., April 26, 2024 at 06:46 am
More quotes
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- RGT Stock
- MXC Stock
